Compare HTZWW & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HTZWW | CMMB |
|---|---|---|
| Founded | 1918 | 2004 |
| Country | United States | Israel |
| Employees | 26000 | N/A |
| Industry | Rental/Leasing Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | 10.8M |
| IPO Year | N/A | 2023 |
| Metric | HTZWW | CMMB |
|---|---|---|
| Price | $0.99 | $2.25 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $25.00 |
| AVG Volume (30 Days) | ★ 190.1K | 104.3K |
| Earning Date | 02-13-2025 | 05-21-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 101.67 |
| EPS | N/A | ★ 0.04 |
| Revenue | ★ $9,049,000,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $56.75 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.98 | $0.87 |
| 52 Week High | $4.41 | $3.86 |
| Indicator | HTZWW | CMMB |
|---|---|---|
| Relative Strength Index (RSI) | 16.13 | 74.41 |
| Support Level | N/A | $1.48 |
| Resistance Level | $2.71 | $2.80 |
| Average True Range (ATR) | 0.20 | 0.17 |
| MACD | -0.13 | 0.05 |
| Stochastic Oscillator | 0.63 | 84.04 |
Hertz Global Holdings Inc is engaged principally in the business of renting vehicles through its Hertz, Dollar and Thrifty brands. The company has two reportable segments: i) Americas RAC: Rental of vehicles, as well as sales of vehicles and value-added services, in the U.S., Canada, Latin America and the Caribbean, ii) International RAC: Rental of vehicles, as well as sales of vehicles and value-added services, in locations other than the U.S., Canada, Latin America and the Caribbean. The company maintains a substantial network of company-operated rental locations, a majority of which are in Europe, and has franchisees and partners that operate rental locations under brands. Geographical markets include North America, Europe, Pacific Asia, Middle East and Africa, and Latin America.
Chemomab Therapeutics Ltd is a clinical-stage biotechnology company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases.